N. IbrahimPrabha, Jiazhong Zhang, Chao Zhang, G. Bollag
{"title":"第26章-病例史:Vemurafenib,一种有效的、选择性的、一流的BRAF突变体抑制剂,用于治疗转移性黑色素瘤","authors":"N. IbrahimPrabha, Jiazhong Zhang, Chao Zhang, G. Bollag","doi":"10.1016/B978-0-12-417150-3.00026-0","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":8033,"journal":{"name":"Annual Reports in Medicinal Chemistry","volume":"48 1","pages":"435-449"},"PeriodicalIF":0.0000,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/B978-0-12-417150-3.00026-0","citationCount":"1","resultStr":"{\"title\":\"Chapter Twenty-Six – Case History: Vemurafenib, a Potent, Selective, and First-in-Class Inhibitor of Mutant BRAF for the Treatment of Metastatic Melanoma\",\"authors\":\"N. IbrahimPrabha, Jiazhong Zhang, Chao Zhang, G. Bollag\",\"doi\":\"10.1016/B978-0-12-417150-3.00026-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":8033,\"journal\":{\"name\":\"Annual Reports in Medicinal Chemistry\",\"volume\":\"48 1\",\"pages\":\"435-449\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2013-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/B978-0-12-417150-3.00026-0\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annual Reports in Medicinal Chemistry\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://doi.org/10.1016/B978-0-12-417150-3.00026-0\",\"RegionNum\":4,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Chemistry\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annual Reports in Medicinal Chemistry","FirstCategoryId":"92","ListUrlMain":"https://doi.org/10.1016/B978-0-12-417150-3.00026-0","RegionNum":4,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Chemistry","Score":null,"Total":0}
Chapter Twenty-Six – Case History: Vemurafenib, a Potent, Selective, and First-in-Class Inhibitor of Mutant BRAF for the Treatment of Metastatic Melanoma
期刊介绍:
Annual Reports in Medicinal Chemistry provides timely and critical reviews of important topics in medicinal chemistry with an emphasis on emerging topics in the biological sciences that are expected to provide the basis for entirely new future therapies.